Literature DB >> 17942786

A high-throughput soft agar assay for identification of anticancer compound.

Steven N Anderson1, Danli L Towne, David J Burns, Usha Warrior.   

Abstract

A 384-well soft agar assay was developed to identify potential novel anticancer compounds. Normally used to detect cell transformation, the assay is used here to quantitate cell proliferation in a 3-dimensional (3-D) anchorage-independent format. HCC827 cells, which are highly sensitive to epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors, were used to develop the method and a set of 9600 compounds used to validate the assay. Results were compared to a monolayer assay using the same compound set. The assay provides a robust method to discover compounds that could be missed using traditional monolayer formats.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17942786     DOI： 10.1177/1087057107306130

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN： 1087-0571


  17 in total

Review 1.  Drugging the undruggable RAS: Mission possible?

Authors:  Adrienne D Cox; Stephen W Fesik; Alec C Kimmelman; Ji Luo; Channing J Der
Journal:  Nat Rev Drug Discov       Date:  2014-10-17       Impact factor: 84.694

2.  Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells.

Authors:  Sachi Horibata; Tommy V Vo; Venkataraman Subramanian; Paul R Thompson; Scott A Coonrod
Journal:  J Vis Exp       Date:  2015-05-20       Impact factor: 1.355

Review 3.  High-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional models.

Authors:  Natalia J Martinez; Steven A Titus; Amanda K Wagner; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2015-09-22       Impact factor: 6.098

4.  Original Research: Featured Article: Imatinib mesylate (Gleevec) inhibits Notch and c-Myc signaling: Five-day treatment permanently rescues mammary development.

Authors:  Robert Callahan; Barry A Chestnut; Ahmed Raafat
Journal:  Exp Biol Med (Maywood)       Date:  2016-08-21

Review 5.  The production of 3D tumor spheroids for cancer drug discovery.

Authors:  Shilpa Sant; Paul A Johnston
Journal:  Drug Discov Today Technol       Date:  2017-04-14

6.  Activating HER2 mutations in HER2 gene amplification negative breast cancer.

Authors:  Ron Bose; Shyam M Kavuri; Adam C Searleman; Wei Shen; Dong Shen; Daniel C Koboldt; John Monsey; Nicholas Goel; Adam B Aronson; Shunqiang Li; Cynthia X Ma; Li Ding; Elaine R Mardis; Matthew J Ellis
Journal:  Cancer Discov       Date:  2012-12-07       Impact factor: 39.397

7.  Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability.

Authors:  Jingjie Zhang; Weiming Ouyang; Jingxia Li; Dongyun Zhang; Yonghui Yu; York Wang; Xuejun Li; Chuanshu Huang
Journal:  Toxicol Appl Pharmacol       Date:  2012-06-28       Impact factor: 4.219

8.  Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.

Authors:  Miranda Dennis; Guanyu Wang; Jie Luo; Yuan Lin; Mariam Dohadwala; Elliot Abemayor; David A Elashoff; Sherven Sharma; Steven M Dubinett; Maie A St John
Journal:  Otolaryngol Head Neck Surg       Date:  2012-05-07       Impact factor: 3.497

9.  ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis.

Authors:  Katarzyna Bogucka; Federico Marini; Sebastian Rosigkeit; Janine Schloeder; Helmut Jonuleit; Kerstin David; Margarita Schlackow; Krishnaraj Rajalingam
Journal:  Cancer Gene Ther       Date:  2020-10-17       Impact factor: 5.987

10.  Advanced cell culture techniques for cancer drug discovery.

Authors:  Carrie J Lovitt; Todd B Shelper; Vicky M Avery
Journal:  Biology (Basel)       Date:  2014-05-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.